Ardelyx reports FY2024 revenue $333.6M; narrows net loss to $39.1M; provides 2025 guidance

ARDELYX, INC.

2024-FY EPS reported -$0.17 revenue$333,615,000

Total revenue $333.6M in 2024, up from $124.5M in 2023; driven by IBSRELA ($158.3M) and XPHOZAH ($160.9M) sales.
Net loss narrowed to $39.1M ($0.17 per share) from $66.1M ($0.30 per share) in 2023.
Cash and investments ended at $250.1M; drew $49.7M under term loan in Q4 2024.
IBSRELA 2025 net sales guidance: $240–250M; reaffirmed peak combined sales potential of $1.75B.
SG&A expenses rose to $258.7M from $134.4M due to sales team expansion and XPHOZAH launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.